2024
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR/R large B-cell lymphomaLarge B-cell lymphomaCenter for International Blood and Marrow Transplant ResearchCytokine release syndromeDuration of responseLiso-celData cutoffRisk of cytokine release syndromeCAR-T cell productsDuration of response rateHigh-risk disease featuresMedian duration of responseReal-world population of patientsB-cell lymphomaTreated with corticosteroidsCAR+ T cellsMarrow Transplant ResearchT cell productionStudy of US patientsPopulation of patientsOne-time infusionReal-world populationReal-world studyCellular therapy registry
2023
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Palomba M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood 2023, 142: 104. DOI: 10.1182/blood-2023-180242.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR LBCLLarge B-cell lymphomaCytokine release syndromeProgression-free survivalDuration of responseReal-world clinical effectivenessHigh-grade B-cell lymphomaLiso-celInternational Prognostic IndexB-cell lymphomaOverall survivalSystemic therapyReal-world studyData cutoffPostmarketing studyMedian timeClinical effectivenessClinical studiesFavorable benefit/risk profileReal-world settingMedian DORMedian progression-free survivalBenefit/risk profileCAR T-cell products